Women's Health

Baker explains how smartwatch sleep data can open clinical conversations about menopausal sleep disturbance but emphasizes the importance of patient-reported outcomes.

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.

Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

ACOG 2026: CDC data show many pregnancy-related deaths may be preventable through better care coordination, access, and follow-up.

Despite waning direct impact of COVID-19, US pregnancy-related mortality remains higher than before the pandemic, driven by persistent cardiovascular, infectious, and hemorrhagic causes.

Global experts have redefined PCOS as PMOS, spotlighting metabolic and heart risks to speed diagnosis, reduce stigma, and improve care.

MR-100A-01 weekly contraceptive patch data will be presented ahead of an FDA decision on the investigational lower-estrogen product.

Highlights include time-efficient strategies for primary care clinicians to identify, assess, and treat GSM and other sexual health concerns during menopause.

ACOG 2026: Kathryn Miele, MD, discusses syphilis screening in pregnancy and how clinicians can reduce stigma around testing.

ACOG 2026: Kathryn Miele, MD, discusses syphilis titer interpretation, discordant results, partner treatment, and practical resources for primary care clinicians.

Highlights include clinical gaps in menopause care, postpartum prevention, cervical cancer screening, pregnancy-related infection, and GLP-1 RA exposure.

Pneumococcal vaccination in pregnancy remains underused in high-risk patients. Maria Marcos, MD, reviews new data, barriers to uptake, and practical vaccination steps for primary care.

Jill Liss, MD, outlines how updated evidence, risk stratification, and newer nonhormonal agents can help PCPs confidently manage VMS in everyday practice.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.

ACOG 2026: James A. Simon, MD, discusses what the results mean for frontline clinician confidence in prescribing the non-hormonal VMS treatment.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Late-breaking data presented at ACOG 2026 showed GLP-1 RA exposure before or during early pregnancy was not associated with hypertensive disorders of pregnancy.

ACOG 2026: Jill Liss, MD, details how primary care physicians can safely initiate hormone therapy, manage menopause counseling in brief visits, and more.

ACOG 2026: The new guidance formally introduces clinician-ordered self-collected HPV testing as an option for cervical cancer screening.

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.